New ASCO and EHA 2026 Data Demonstrate Gilead and Kite’s Momentum Across Antibody-Drug Conjugates and Cell Therapy in Oncology
Gilead and Kite will present more than 25 abstracts at ASCO and EHA 2026, highlighting momentum in antibody-drug conjugates and CAR T-cell therapy. Key data includes Phase 3 ASCENT-04 and ASCENT-03 analyses for Trodelvy in first-line metastatic triple-negative breast cancer, supporting potential label expansions and commercial growth.
Key figures
- Abstract count
- more than 25
- Oral presentations
- 6
- Gilead investment usd
- 32000000000
- Trodelvy approval countries
- more than 60
- Trodelvy approval countries bc
- more than 50
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.